Our President & CEO Kazu Kuramori was at the Innate Killer Summit 2019 – Title：GAIA-102 as an NK Cell-Based “Upward Compatible” Modality Over CAR-T-Cell Therapy –

Our President & CEO Kazu Kuramori was at the Innate Killer Summit 2019

– Title：GAIA-102 as an NK Cell-Based “Upward Compatible” Modality Over CAR-T-Cell Therapy –

Themes

• GAIA-102 is a novel immature phenotype of NK cells with a massive killing activity against various types of malignancies
• GAIA-102 eliminates spheroid-forming tumors, which are highly resistant to CAR-T cells
• GAIA-102 is a promising candidate for adoptive immunotherapy of solid tumors as an “upward compatible” modality over CAR-T-cell therapy

Share on